Hepatitis C y B en pacientes con insuficiencia renal crónica y trasplante renal. Historia natural y decisiones terapéuticas

Gisela Romero

Resumen


En esta revisión se presenta una actualización sobre Hepatitis C y B en pacientes con daño renal crónico y trasplantados renales, dando a conocer aspectos epidemiológicos, historia natural de la infección por virus C y B de la Hepatitis, así como indicaciones y contraindicaciones del tratamiento, con algoritmos de manejo.

Texto completo:

PDF

Referencias


Pereira B, Levey A. Hepatitis C virus infection in dialysis and renal transplantation. Kidney Int 1997;51:981-99.

Garassini SM, Garassini Ch M. Hepatitis C. ¿Cómo se transmite? ¿Se puede prevenir? Gen 2000;54:116-35.

Schneeberger PM, Keur I, Van-der Vliet W, Van-Hoek K, Boswijk H, Van-Loon AM, Van-Dijk WC, et al. Hepatitis C virus infection in diálisis centres in The Netherlands: a nacional survey by serological and molecular methods. J Clin Microbiol 1998;36:1711- 1715.

Fabrizi F, Poordad F, Martin P. Hepatitis C infection and the patient with end-stage renal disease. Hepatology 2002;36:3-10.

Martin P, Friedman LS. Chrinic viral hepatitis and the management of chronic renal failure. Kidney Int 1995;47:1231-1241.

Fabrizi F, Martin P, Dixit V, Brezina M, Cole MJ, Gerosa S, Vinson S, et al. Acquisition of Hepatitis C virus in hemodialysis patients: a prospective study by branched DNA signal amplification assay . Am J Kidney Dis 1998;31:647-654.

Mathurin P, Mouquet C, Poynard T, Sylla Ch, Benalia H, Fretz C, et al. Impact of hepatitis B and C virus on kidney transplantation outcome. Hepatology 1999;29:257-63.

Djordjevic V, Stojanovic K, Stojanovic M, Stefanovic V. Prevention of nosocomial transmission of hepatitis C infection in a hemodialysis unit. A prospective study. Int J Artif Organs 2000;23: 181-188.

Nakayama E, Akiba T, Marumo F, Sato C. Prognosis of antihepatitis C virus antibody-positive patients on regular hemodialysis therapy. J Am Soc Nephrol 2000;11:1896-1902.

Zuramay C, Páez R, León R, Ruiz ME, Infante M. Evaluación histological de infección por hepatitis C en pacientes en hemodiálisis. Gastroent y Hepatol 2002;25 suppl 2:13.

Vosnides GG. Hepatitis C in renal transplantation. Kidney Int. 1997;52:843-861.

Macellin P, Boyer N, Behamoud Jp, Erlingy S. Interferon alfa therapy for chronic hepatitis C in special patient populations. Dig Dis Sci 1996;41:126S-130S.

Bruchfeld A, Stahle L, Anderson J, Schvarea R. Ribavirin treatment in dialysis patients with chronic hepatitis C infection a pilot study. J Viral Hep 2001;8:287-92.

Pereira B, Natov S, Bouthot B, et al. Rffect of hepatitis C infection and renal transplantation on survival in end-stage renal disease. Kidney Int 1998;53:1374-81.

Pol S, Thiers V, Carnot F, et al. Efficacy and tolerance of alfa 2 b interferon therapy on HCV infection of hemodialized patients. Kidney Int 1995;47:1412-8.

Rao KV, Anderson RW, Kasiske BL, Dahe RC. Value of liver biopsy in the evaluation and management of chronic liver disease in renal transplant recipients. Am J Med 1993;94:241-250.

Lamb M, Marks I, Wynohradnyk L. 40 KDa peginterferon alfa 2 a (Pegasys) can administered safely inpatients with end stage renal disease. Hepatology 2001;34:826 A.

Chen–Hua Liu and Jia-Horng Kao. Treatment of hepatitis C virus infection in patients with end-stage renal disease. Journal of Gastroenterology and Hepatology 2010; 1440-1746.

Fabrizi F, Messa P, Martin P. Transmission of hepatitis C virus infection in hemodialysis: current concepts. Int J Artif Organs 2008;31:1004-16.

Fabrizi F, Takkouche B , Lunghi G , Dixit V , Messa P, Martin P. The impact of hepatitis C virus infection on survival in dialysis patients: meta-analysis of observational studies. J Viral Hepat. 2007;14:697-703.

Zucker K, Cirocco R, Roth D, Olson H, Burke GU, Nery J, Esquenazi V, et al. Depletion of hepatitis C virus from procured kidneys using pulsatile perfusion preservation. Transplantation 1994;57:832-840.

Pawa S, Mutchnick M, Ehrinfreis M, et al. Patients with chronic hepatitis C and chronic renal insufficiency or end stage renal. Disease respond poorly to interferon monotherapy. Hepatology 2004;40 (Suppl 1):332 A.

Russo M, Ghalib R, Sigal S, et al. A multicentre randomized trial of pegylated interferon alfa 2b monotherapy (peg-intron) en patients with chronic hepatitis C and stage kidney disease on dialysis. Hepatology 2004;40(Suppl 1):339 A.

Nutt A, Hassan H, Lindsey J, Lamps L, Raufman J. Liver biopsy in the evaluation of patients with chronic hepatitis C who have repeatedly normal or near-normal serum alanine aminotransferase levels. Am J Med 2000;109: 62-4.

Koff J, Younossi Z. Hepatitis C with normal liver enzymes: to treat or not to treat. Pro: Most patients should be treated. Am J Gastroenterol 2004;99:972-3.

Reddy KR. Hepatitis C with normal liver enzymes: to treat or not to treat. Con: most patients should not be treated. Am J Gastroenterol 2004;99:973-5.

Jacobson I, Russo M, Lebovics E, et al. Interferon alfa-2b and ribavirin for patients with chronic hepatitis C and normal ALT: final results. Gastroenterology 2002;36:A-627.

Zeusem S, Diago M, Gane E, et al. Fort he PEGASYS Study NR16071 Investigator Group. Peginterferon alfa-2 a (40 xxxxx=) and ribavirin in patients with chronic hepatitis C and normal aminotransferase levels. Gastroenterology 2004;127:1724-32.

The NIH Consensus Development Conference Statement: Management of Hepatitis C. Hepatology 1997;26(Suppl 1):2S- 10S.

The NIH Consensus Development Conference Statement: Management of Hepatitis C. Hepatology 2002;36(Suppl 5):3S- 20S.

Ping-Nam Wong, Tang–Tat Fung, et al. Hepatitis B virus infection in dialysis patients. Journal of Gastroenterology and Hepatology 2005;20:1641-1651.

Perrillo Robert. Hepatitis B and renal transplation: Securing the Sword of Damocles. Hepatology;36(5):1042-1045.

Fabrizi F, Lunghi G, Martin P. Hepatitis B virus infection in hemodialysis: recent discoveries. J Nephrol 2002;15:463-8.

Campistol JM, Esforzado N, Martinez J, et al. Efficacy and tolerance of interferon-alpha (2b) in the treatment of chronic hepatitis C virus infection in haemodialysis patients. Pre- and post-renal transplantation assessment. Nephrol. Dial. Transplant. 1999;14: 2704-9.

Fabrizi F, Dulai G, Dixit V, Bunnapradist S, Martin P. Lamivudine for the treatment of hepatitis B virus-related liver disease after renal transplantation: meta-analysis of clinical trials. Transplantation 2004;77:859-64.

Lok AS, McMahon BJ, Practice Guidelines Committee, American Association for the Study of Liver Diseases (AASLD). Chronic hepatitis B: update of recommendations. Hepatology 2004;39: 857-61.




DOI: http://dx.doi.org/10.61155/gen.v66i1.188

VIDEOS GEN



Pseudoquiste pancreático postraumático y Síndrome del Ducto Pacreático Desconectado.
Autor: Dr. Freddy Pereira Graterol

CPRE. Sitio de sección del ducto pancreático principal

Drenaje transgástrico de pseudoquiste pancreático

CPRE. Sección del ducto hepático izquierdo por traumatismo de abdomen





Cavernomatosis portal y colangiopatía portal. A propósito de un caso.
Autora: Dra. Anais Karina García Yaraure
 

Cavernomatosis portal Pre Colocacion de TIPS.

 

Cavernomatosis portal Post Colocacion de TIPS.




 

 

 

 

 

 

LatindexSciELOCrossref

Revista GEN
ISSN: 0016-3503 e-ISSN: 2477-975X
Depósito Legal: pp197602CS570
Sociedad Venezolana de Gastroenterología
Este trabajo está licenciado bajo Creative Commons 4.0.
Revista GEN no almacena ningun tipo de cookies ni variables de sesion de usuarios